Literature DB >> 16000276

Sympathetic denervation and reinnervation after the maze procedure.

Megumi Mabuchi1, Michiaki Imamura, Naoki Kubo, Koichi Morita, Kazuyuki Noriyasu, Takahiro Tsukamoto, Keisyu Yasuda, Nagara Tamaki.   

Abstract

UNLABELLED: We evaluated serial changes in cardiac sympathetic nerve distribution using 123I-metaiodobenzylguanidine (123I-MIBG) after the Maze procedure. The Maze procedure, in which multiple incisions are made in the atrium, has been concomitantly performed with mitral valve (MV) surgery in an attempt to eliminate atrial fibrillation (AF). Although attenuation of the sinoatrial node response to exercise and a reduction of left ventricular function (left ventricular ejection fraction [LVEF]) in early stages after the Maze procedure have been suggested, factors leading to these changes have not been clarified.
METHODS: Thirteen patients with MV disease were enrolled in this study. Six of them had undergone MV surgery and the Maze procedure (Maze+), and 7 had undergone MV surgery without the Maze procedure (Maze-). All patients underwent cardiac 123I-MIBG imaging preoperatively and 10 d and 1 y after surgery to assess 123I-MIBG uptake (heart-to-mediastinum count ratio of early planar images [H/M]) and the washout rate (WR). Radionuclide ventriculography was also performed to calculate LVEF 3 d after each 123I-MIBG imaging.
RESULTS: The LVEF of the Maze+ group significantly decreased 10 d after surgery (44.2 +/- 4.8; mean +/- SD) compared with that before surgery (60.3 +/- 6.9; P < 0.05) and significantly increased at 1 y (65.2 +/- 2.9) compared with that at 10 d (P < 0.05). In the Maze- group, there was no significant change 10 d (53.0 +/- 12.3) and 1 y (58.6 +/- 4.8) after surgery compared with that before surgery (60.4 +/- 4.6) (P = not significant, each). In the Maze+ group, the H/M (1.51 +/- 0.18) was significantly lower at 10 d after than that at the preoperative stage (1.90 +/- 0.25; P < 0.05) but significantly recovered at 1 y (2.23 +/- 0.18; P < 0.05) with a similar transient increase in the WR (36.7% +/- 6.1% at preoperative stage; 46.9% +/- 3.4% at 10 d; 39.9% +/- 6.5% at 1 y; P < 0.05, each). On the other hand, the Maze- group did not show a significant change in the H/M (1.94 +/- 0.32, 2.06 +/- 0.18, and 2.13 +/- 0.17, respectively; P = not significant, each) but did exhibit a significant decrease in the WR (40.4% +/- 5.1%, 37.0% +/- 5.1%, and 32.9% +/- 2.5%, respectively; P < 0.05, each). Changes in the H/M of both groups significantly correlated with the change in LVEF (r = 0.82; P < 0.05), and the WR showed a significant inverse correlation with changes in the LVEF (r = -0.81; P < 0.05).
CONCLUSION: Cardiac sympathetic nerves were denervated at early stage and reinnervated at late stage after the Maze procedure. Such adrenergic nerve changes may be correlated, at least in part, with changes in left ventricular function after this procedure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000276

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

1.  Pulmonary vein isolation and the Cox maze procedure only partially denervate the atrium.

Authors:  Shelly C Lall; Kelley V Foyil; Shun-ichiro Sakamoto; Rochus K Voeller; John P Boineau; Ralph J Damiano; Richard B Schuessler
Journal:  J Thorac Cardiovasc Surg       Date:  2008-03-04       Impact factor: 5.209

2.  Ganglionated plexus ablation for atrial fibrillation: Just because we can, does that mean we should?

Authors:  Una Buckley; Pradeep S Rajendran; Kalyanam Shivkumar
Journal:  Heart Rhythm       Date:  2017-01       Impact factor: 6.343

Review 3.  Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the atrial autonomic nervous system.

Authors:  Rishi Arora
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-08-01

Review 4.  The potential utility of (123)I-mIBG in atrial fibrillation and in the electrophysiology laboratory.

Authors:  Marc Ovadia; Kristin S Duque
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

5.  Significance of cardiac sympathetic nervous system abnormality for predicting vascular events in patients with idiopathic paroxysmal atrial fibrillation.

Authors:  Yasushi Akutsu; Kyouichi Kaneko; Yusuke Kodama; Hui-Ling Li; Jumpei Suyama; Akira Shinozuka; Takehiko Gokan; Mitsuharu Kawamura; Taku Asano; Yuji Hamazaki; Kaoru Tanno; Youichi Kobayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-17       Impact factor: 9.236

Review 6.  Neuronal imaging using SPECT.

Authors:  Shohei Yamashina; Jun-ichi Yamazaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

Review 7.  Neuronal imaging using SPECT.

Authors:  Shohei Yamashina; Jun-ichi Yamazaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 10.057

8.  Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of 11C-HED PET and 123I-MIBG SPECT.

Authors:  Yusuke Tokuda; Mamoru Sakakibara; Keiichiro Yoshinaga; Shiro Yamada; Kiwamu Kamiya; Naoya Asakawa; Takashi Yoshitani; Keiji Noguchi; Osamu Manabe; Nagara Tamaki; Hiroyuki Tsutsui
Journal:  J Nucl Cardiol       Date:  2017-11-27       Impact factor: 5.952

9.  The relationship between global cardiac and regional left atrial sympathetic innervation and epicardial fat in patients with atrial fibrillation.

Authors:  Alexander Romanov; Stanislav Minin; Nikita Nikitin; Dmitry Ponomarev; Vitaly Shabanov; Denis Losik; Jonathan S Steinberg
Journal:  Ann Nucl Med       Date:  2021-06-14       Impact factor: 2.668

10.  Pulmonary vein isolation in patients with paroxysmal atrial fibrillation is associated with regional cardiac sympathetic denervation.

Authors:  Christian Wenning; Philipp S Lange; Christoph Schülke; Alexis Vrachimis; Gerold Mönnig; Otmar Schober; Lars Eckardt; Michael Schäfers
Journal:  EJNMMI Res       Date:  2013-12-21       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.